Based on our above finding that IGF1/IGF1R axis facilitated HOXA13 overexpression and CRC metastasis through transactivating ACLY and IGF1R, we hypothesized that whether the combination of ACLY and IGF1R inhibitors had a synergistic effect on CRC treatment. The gene discussed is ACLY; the disease is colorectal carcinoma.